Literature DB >> 33606005

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients.

Ghulam Rehman Mohyuddin1, Anthony Rooney1, Nicole Balmaceda1, Muhammad Aziz2, Douglas W Sborov3, Brian McClune3, Shaji K Kumar4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33606005      PMCID： PMC7903229          DOI： 10.1182/bloodadvances.2020004017

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  10 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Authors:  Carlos A Ramos; Barbara Savoldo; Vicky Torrano; Brandon Ballard; Huimin Zhang; Olga Dakhova; Enli Liu; George Carrum; Rammurti T Kamble; Adrian P Gee; Zhuyong Mei; Meng-Fen Wu; Hao Liu; Bambi Grilley; Cliona M Rooney; Malcolm K Brenner; Helen E Heslop; Gianpietro Dotti
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

3.  B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Authors:  Adam D Cohen; Alfred L Garfall; Edward A Stadtmauer; J Joseph Melenhorst; Simon F Lacey; Eric Lancaster; Dan T Vogl; Brendan M Weiss; Karen Dengel; Annemarie Nelson; Gabriela Plesa; Fang Chen; Megan M Davis; Wei-Ting Hwang; Regina M Young; Jennifer L Brogdon; Randi Isaacs; Iulian Pruteanu-Malinici; Don L Siegel; Bruce L Levine; Carl H June; Michael C Milone
Journal:  J Clin Invest       Date:  2019-03-21       Impact factor: 14.808

4.  T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

Authors:  Jennifer N Brudno; Irina Maric; Steven D Hartman; Jeremy J Rose; Michael Wang; Norris Lam; Maryalice Stetler-Stevenson; Dalia Salem; Constance Yuan; Steven Pavletic; Jennifer A Kanakry; Syed Abbas Ali; Lekha Mikkilineni; Steven A Feldman; David F Stroncek; Brenna G Hansen; Judith Lawrence; Rashmika Patel; Frances Hakim; Ronald E Gress; James N Kochenderfer
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

5.  A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.

Authors:  Zhiling Yan; Jiang Cao; Hai Cheng; Jianlin Qiao; Huanxin Zhang; Ying Wang; Ming Shi; Jianping Lan; Xiaoming Fei; Lai Jin; Guangjun Jing; Wei Sang; Feng Zhu; Wei Chen; Qingyun Wu; Yao Yao; Gang Wang; Jing Zhao; Junnian Zheng; Zhenyu Li; Kailin Xu
Journal:  Lancet Haematol       Date:  2019-08-01       Impact factor: 18.959

Review 6.  Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2020-05       Impact factor: 10.047

7.  A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.

Authors:  Di Wang; Jue Wang; Guang Hu; Wen Wang; Yi Xiao; Haodong Cai; Lijun Jiang; Li Meng; Yongkun Yang; Xiaoxi Zhou; Zhenya Hong; Zheng Yao; Min Xiao; Liting Chen; Xia Mao; Li Zhu; Jin Wang; Lugui Qiu; Chunrui Li; Jianfeng Zhou
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

8.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

Review 9.  Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.

Authors:  Shebli Atrash; Syed Abbas Ali; Saad Z Usmani
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-09-18
  10 in total
  5 in total

Review 1.  Progress on CAR-T cell therapy for hematological malignancies.

Authors:  Kejia Hu; Yue Huang; Yongxian Hu; He Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

2.  AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.

Authors:  Chunyan Gu; Yajun Wang; Lulin Zhang; Li Qiao; Shanliang Sun; Miaomiao Shao; Xiaozhu Tang; Pinggang Ding; Chao Tang; Yuhao Cao; Yanyan Zhou; Mengjie Guo; Rongfang Wei; Nianguang Li; Yibei Xiao; Jinao Duan; Ye Yang
Journal:  J Exp Clin Cancer Res       Date:  2022-01-06

3.  Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.

Authors:  Wenjing Luo; Chenggong Li; Yinqiang Zhang; Mengyi Du; Haiming Kou; Cong Lu; Heng Mei; Yu Hu
Journal:  BMC Cancer       Date:  2022-01-24       Impact factor: 4.430

4.  Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma.

Authors:  Yujun Wei; Jinying Wang; Fei Chen; Xin Li; Jiajia Zhang; Man Shen; Ran Tang; Zhongxia Huang
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

Review 5.  Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.

Authors:  Eyal Lebel; Boaz Nachmias; Marjorie Pick; Noa Gross Even-Zohar; Moshe E Gatt
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.